The changes of blood coagulation in surgical patients with lung cancer

Chinese Journal of Lung Cancer

Volumn 13, Issue 2, 2010, Pages 136-139

  Xu, Chengcheng ^a   Fu, Xiangning ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Blood coagulation; Lung neoplasms; Thrombophilia; Venous thromboembolis

Indexed keywords

D DIMER; FIBRINOGEN;

ARTICLE; BLOOD CLOTTING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG METASTASIS; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; OPERATION DURATION; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PROTHROMBIN TIME; SURGICAL PATIENT; THROMBOCYTE COUNT;

ADULT; AGED; BLOOD COAGULATION; FEMALE; FIBRINOGEN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROSPECTIVE STUDIES; PROTHROMBIN TIME;

EID: 77949294793     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.02.11     Document Type: Article

References (17)

1. Trousseau A ed. Clinique médicale de l'Hôtel-Dieu de Paris. 2nd ed. France: J. B. Balliere et Fils, 1865. 654-712.
2. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol, 2009, 27(29): 4834-4838.
3. Molnar S, Guglielmone H, Lavarda M, et al. Procoagulant factors in patients with cancer. Hematology, 2007, 12(6): 555-559.
4. Marinho FC, Takagaki TY. Hypercoagulability and lung cancer. J Bras Pneumol, 2008, 34(5): 312-322.
5. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost, 2008, 6(4): 601-608.
6. Blom JW, Osanto S, Rosendaal FR. The risk of a venousthrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost, 2004, 2(10): 1760-1765.
7. Jiang ZH, Sang HY, Ge H, et al. The study of prethrombotic state in patients with lung cancer. Chin J Lung Cancer, 2009, 12(1): 22-26.
8. Zhao Y, Yang SJ, Zhao HX. Changes of coagulation and clinical significance in NSCLC. Chin J Clin Oncol, 2007, 41(21): 1250-1252.
9. Świniarska J, Żekanowska E, Dancewicz M, et al. Pneumonectomy due to lung cancer results in a more pronounced activation of coagulation system than lobectomy. Eur J Cardiothorac Surg, 2009, 36(6): 1064-1068.
10. Goldin-Lang P, Tran QV, Fichtner I, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep, 2008, 20(1): 123-128.
11. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol, 2005, 6(6): 401-410.
12. Wang ZY, Li JZ, Yuan CD ed. Thrombosis & Hemostasis Basic Principles & Clinical Practices. 3rd ed. Shanghai: Shanghai Scientific Publication, 2004. 669-678.
13. Wu MC, Wu ZD ed. Hang JiaSi Surgery. 7th ed. BeiJing: People Health Publishing House, 2008. 1228-1238.
14. Wang XA, Jiang GN, Li WT, et al. DVT and PE after thoracic surgery. Chin J Surg, 2007, 45(18): 1292-1295.
15. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol, 2009, 27(29): 4902-4911.
16. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 2002, 346(13): 975-980.
17. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized openlabel study. J Thromb Haemost, 2006, 4(11): 2384-2390.